References
- Vietri J, Turner SJ, Tian H, et al. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. Ann Allergy Asthma Immunol 2015;115:306-11
- Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-209.e5
- Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exper Allergy 2015;45:547-65
- Moolani Y, Lynde C, Sussman G. Advances in understanding and managing chronic urticaria. F1000Res. 2016 Feb 16;5. pii: F1000 Faculty Rev-177.
- Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
- Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol 2014;133:1270-7
- Genentech. Xolair prescribing information [Internet]. 2015. South San Francisco, California, United States: Genentech, Inc. Available online at: http://www.gene.com/download/pdf/xolair_prescribing.pdf. Accessed March 30, 2016
- Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013;132:101-9
- Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013;368:924-35
- Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128:567-73.e1
- Anthem. Anthem Xolair Medical Policy [Internet]. Anthem; 2015. Indianapolis, Indiana, United States: Anthem, Inc. Available online at: https://www.anthem.com/medicalpolicies/policies/mp_pw_a050293.htm. Accessed March 30, 2016
- Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory utricaria. Allergy Asthma Proc 2013;34:446-52
- Clark JJ, Secrest AM, Hull CM, et al. The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: retrospective chart review. J Am Acad Dermatol 2016;74:1274-5